BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 24, 2012
View Archived Issues
Researchers from Canada link CX3CR1 to neural degeneration in CSM
Read More
JNJ-41477670: a novel TRPA1 antagonist with a promising pharmacokinetic profile
Read More
Millennium presents first clinical results for two of its anticancer compounds
Read More
Genetic variations shared between obesity and ADHD identified
Read More
Durable immune responses seen in vivo with HSV-2 vaccine
Read More
Prosensa advances DMD candidates, obtains orphan drug designations
Read More
PTC Therapeutics receives NIH funding for dengue research
Read More
Biotica Technology discloses new cyclophilin A inhibitors
Read More
Amicus achieves target enrollment in phase III migalastat hydrochloride study
Read More
Interim 6-month results of 2-year extension STEPS2 trial presented
Read More
Novel antibacterial agents patented by Brown University
Read More
Lilly reports results from three phase III AWARD trials
Read More
Researchers at GE Healthcare divulge new PET imaging agents
Read More
AIM Therapeutics commences dosing in phase II AIM-102 trial
Read More
Novel TRPV3 channel inhibitors disclosed by Abbott Laboratories
Read More
Merck & Co. patents new compounds for cancer
Read More
Corcept Therapeutics presents new glucocorticoid receptor antagonists
Read More
FDA approves extended-release formulation of oxcarbazepine
Read More
Cel-Sci reports interim review results from phase III Multikine study
Read More
ISTO Technologies plans phase II NuQu study in discogenic back pain
Read More
LabCorp to develop tuberculosis antimicrobial susceptibility test using B-SMART
Read More
Minimally invasive non-small cell lung cancer model devised
Read More
AnGes and Mitsubishi Tanabe Pharma agree on Collategene U.S. rights
Read More
Avanir receives Michael J. Fox Foundation grant to study AVP-923
Read More
SARcode Bioscience discloses topline results from phase III lifitegrast study
Read More
Cosmo Pharmaceuticals reports data from phase II methylene blue MMX study
Read More